A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

How Does Skyrizi Work for Psoriatic Arthritis? Psoriasis is a type of autoimmune condition, which means that the body’s immune cells attack its own healthy cells.

Medically reviewed by Katlein Franca, MD Guttate psoriasis causes small, round bumps. It's typically triggered by a Streptococcus (strep) bacteria infection. Guttate psoriasis most commonly affects ...

New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL ...

NEW YORK — Skyrizi exhibited efficacy across racial and ethnic groups for the treatment of moderate to severe plaque psoriasis, according to a presentation at the Skin of Color Update 2023 ...

AbbVie (ABBV) said Wednesday its FDA-approved immunology therapy, Skyrizi, outperformed Amgen’s (AMGN) blockbuster therapy, Otezla in plaque psoriasis. Read more here.

Icotrokinra helped 66% of patients with scalp psoriasis and 77% of those with genital psoriasis achieve significantly clear skin compared to 11% and 21% success rate in patients on placebo ...

Researchers from King’s College London (KCL) have investigated the early effects of AbbVie’s immunosuppressant drug, Skyrizi (risankizumab), which could help clinicians develop personalised treatment ...

Innovent’s psoriasis contender to IL-23 drugs like Tremfya and Skyrizi cleared skin in a phase 3 test, setting up an approval request in China.

After triumphing over Novartis’ Cosentyx in a 2020 psoriasis study, Skyrizi has dished out another serving of competitor-busting data. This time, the AbbVie and Boehringer Ingelheim-partnered ...

Citing results published by the British Journal of Dermatology in a head-to-head study, AbbVie’s Skyrizi was deemed more effective when compared to Amgen’s Otezla among adult patients with moderate ...